I recommend an interesting blog:
In it I have read this (matizo that the liraglutida only treats type 2 diabetes):
In the last bulletin pharmacotherapy evaluation of the CEMPS, an analysis of the liraglutida (incredin for the treatment of diabetes mellitus) is published in which it is concluded that:
- It does not imply any therapeutic advance, not even for any group of patients with a special characteristic.It is, therefore a me-too, (equal efficiency as others from the same therapeutic group and similar theoretical security although without studies in phase IV)
- The six studies that endorse it are low or very low quality with design deficiencies, not including morbidity and mortality as an efficacy variable, comparing the molecule with placebo and/or with substances at maximum doses little used in clinical practice (glimepirid), or with substances withdrawn from the market (Rosiglitazone).
- It has the same profile of adverse reactions as the rest of the Anologists of LPG-1 although greater abandonment rates.
- It is suspected that can cause acute pancreatitis and thyroid neoplasms.No long -term security information is available.
- Patients have to prick it because it has no oral form
- It is double the face that the most expensive insulin (glargine) and three times more expensive than the insulin NPH.
I understand that the AEMPS (Spanish regulatory agency), in its long career of disregard in their actions with the consequences on the health of citizens and the sustainability of the public health system, has admitted its commercialization.He is so aseptic in his verdicts ...
But I cannot understand that this government, through its General Directorate of Pharmacy and Health Products has admitted its public financing.
Because, is there any "Candida Alma" in the ministry that does not know that, after its public financing, a network of commercial agents is triggered that knowing (or without knowing) that their product is not better than others, they must use allThe "possible strategies" to position it among the medical prescription?Do you not know that many doctors will be receptive to such strategies (I will once analyze the profile of these doctors) and this will produce an economic waste of the system and a decrease in the safety of treated patients?
There are many voices that have requested, for years, a change in the medicine policy in this country, without going any further, in this same blog I have published two entries in this regard ("it has shown to be inferior" and "and" and "and" and "and" and "and" and "and" and "and" and "and" and "and" and "and" and "The AEMPS still does not find out ”) but there are many more authors.But if this policy has always been unsustainable, with the current economic crisis it is morally reprehensible.
It cannot be that sanitary services are being closed and eliminating health personnel contracts that affect health care and life of people and a drug policy is perpetuated that only benefits the economic interests of large pharmaceutical industries and notThe health of citizens.
I think it's time to say enough, I think it's time to denounce these policies that prioritize companies and their industrial benefits.The dozens of millions of euros that are going to be wasteing an unnecessary product could devote themselves to maintaining those health services that are closing.